Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1
- 21 June 2016
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (12) , 1570-1581
Abstract
Tamoxifen is metabolically activated to 4-hydroxytamoxifen and endoxifen by cytochrome P450 (CYP). CYP phenotypes have been correlated to tamoxifen outcomes, but few have considered drug interactions or combinations of genes. Fewer still have considered ABCB1, which encodes P-glycoprotein and transports active tamoxifen metabolites. We compared the concentrations of tamoxifen and metabolites in 116 breast cancer patients with predicted phenotypes for CYP2D6, CYP3A4, CYP3A5, CYP2C9, CYP2C19 and ABCB1 genotypes. A significant correlation between CYP2D6 phenotypes and tamoxifen metabolites was seen, strongest for endoxifen (pABCB1 genotypes. Lower concentrations of endoxifen and endoxifen/4-hydroxytamoxifen ratios were seen with impaired CYP2C9 (p = 0.05 and 0.03, respectively) if patients had the same CYP2D6 phenotype and were not taking a CYP2D6 or CYP2C19 inhibitor. Lower concentrations of 4-hydroxytamoxifen were seen for impaired CYP2C19 when ABCB1 SNP3435 was nonvariant (p = 0.04). With three impaired CYP phenotypes, endoxifen concentrations were lower than if only CYP2D6 was impaired (p = 0.05). When CYP2D6 was impaired, ABCB1 3435 CC (rs1045642) was associated with significantly higher endoxifen (p = 0.03). Thus, impairment in CYP2C9, CYP2C19, or ABCB1 contributes to a lower steady-state endoxifen concentration at the dose studied. These studies represent an improved way of examining relationships between pharmacogenetics, drug concentrations, and clinical outcomes and warrants study in larger populations. This article is protected by copyright. All rights reservedKeywords
This publication has 34 references indexed in Scilit:
- Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysisAsian Pacific Journal of Cancer Prevention, 2014
- Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancerThe Pharmacogenomics Journal, 2014
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and TransportersDrug Metabolism and Pharmacokinetics, 2012
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsThe Lancet, 2011
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsBritish Journal of Clinical Pharmacology, 2011
- Pharmacogenomics of Tamoxifen TherapyClinical Chemistry, 2009
- Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6The Journal of Pharmacology and Experimental Therapeutics, 2004
- Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of TamoxifenBreast Cancer Research and Treatment, 2004
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998